MXC — MGC Pharmaceuticals Share Price
- AU$15.87m
- AU$9.18m
- AU$3.39m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 11.71 | ||
Price to Tang. Book | 11.71 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 11.99 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -316.25% | ||
Return on Equity | n/a | ||
Operating Margin | -1175.76% |
Financial Summary
Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | AU$m | 0.66 | 2.08 | 3 | 4.73 | 3.39 | 13 | 19.1 | 47.31% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
MGC Pharmaceuticals Ltd is an Australia-based pharmaceutical company. The Company is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its central business strategy revolves around the development and supply of medicines, responding to the increasing demand in the medical markets of Europe, North America, and Australasia. It maintains a robust development pipeline that addresses two prevalent medical conditions, with additional products in the developmental stages. Its clinical trials include CannEpil, CimetrA and ArtemiC. It has a growing patient base in Australia, the United Kingdom, Brazil, and Ireland. The Company's wholly owned subsidiaries include MGC Pharma (UK) Limited, MGC Research (Aus) Pty Ltd, and Medicinal Cannabis Clinics Pty Ltd.
Directors
- Brett Mitchell CHM
- Roby Zomer CEO
- Amir Polak CTO
- Nativ Segev EDR
- Nicole Godresse OTH
- Sabina Suljakovic OTH
- Rachel Kerr SEC
- David Lim SEC (50)
- Stephen Parker NED (62)
- Evan Hayes NID
- Ross Grant Thomas Walker NID
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 21st, 2005
- Public Since
- December 21st, 2006
- No. of Shareholders
- 10,119
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 36,491,631
- Address
- 1202 Hay Street, PERTH, 6005
- Web
- https://mgcpharma.com.au/
- Phone
- +61 863823390
- Auditors
- Ernst & Young
Latest News for MXC
Upcoming Events for MXC
Full Year 2024 MGC Pharmaceuticals Ltd Earnings Release
Similar to MXC
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Auscann group
Australian Stock Exchange - SEATS
Biome Australia
Australian Stock Exchange - SEATS
FAQ
As of Today at 18:14 UTC, shares in MGC Pharmaceuticals are trading at AU$0.44. This share price information is delayed by 15 minutes.
Shares in MGC Pharmaceuticals last closed at AU$0.44 and the price had moved by -96.05% over the past 365 days. In terms of relative price strength the MGC Pharmaceuticals share price has underperformed the ASX All Ordinaries Index by -96.49% over the past year.
The overall consensus recommendation for MGC Pharmaceuticals is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
MGC Pharmaceuticals does not currently pay a dividend.
MGC Pharmaceuticals does not currently pay a dividend.
MGC Pharmaceuticals does not currently pay a dividend.
To buy shares in MGC Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.44, shares in MGC Pharmaceuticals had a market capitalisation of AU$15.87m.
Here are the trading details for MGC Pharmaceuticals:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: MXC
Based on an overall assessment of its quality, value and momentum MGC Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in MGC Pharmaceuticals is AU$0.04. That is 90.8% below the last closing price of AU$0.44.
Analysts covering MGC Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.07 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MGC Pharmaceuticals. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -80.32%.
As of the last closing price of AU$0.44, shares in MGC Pharmaceuticals were trading -76.11% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The MGC Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.44.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
MGC Pharmaceuticals' management team is headed by:
- Brett Mitchell - CHM
- Roby Zomer - CEO
- Amir Polak - CTO
- Nativ Segev - EDR
- Nicole Godresse - OTH
- Sabina Suljakovic - OTH
- Rachel Kerr - SEC
- David Lim - SEC
- Stephen Parker - NED
- Evan Hayes - NID
- Ross Grant Thomas Walker - NID